Scientific relevance

BioGaia recognizes the importance of clinical trials to establish the properties but more importantly the safety of the probiotics used in its products.

As such, BioGaia has conducted numerous clinical trials on the use of Limosilactobacillus reuteri strains as a food supplement. To date, there have been 184 clinical studies on BioGaia’s human strains of Limosilactobacillus reuteri with approximately 17,200 individuals of all ages (72 percent children). Limosilactobacillus reuteri has proven effective in regulating the bacterial balance in the gut and completely safe for both children and adults. The results of studies have been published in 180 articles in various scientific journals, a testimony to its high relevance.

Not all probiotics are equal

Although valuable, not all bacteria referred to as probiotics are equal. 

Limosilactobacillus reuteri Protectis (DSM 17938) is one of the most well-researched strains of probiotic bacteria available, in particular among infants and children up to three years old. This specific strain has been tested in 163 completed clinical trials with approximately 15,365 individuals, 66 percent of which were children. The use of Limosilactobacillus reuteri Protectis has proven entirely safe, which is particularly important for parents who are looking to supplement a baby’s diet. The publication of the studies’ results in over 150 professional journal articles is further proof of the probiotic’s significance among experts.

For detailed information, please visit BioGaia

A selection of studies

We use cookies to make your experience of our website better.
Using this website means you are OK with this. Find out more.